Texas Original Launches State’s First Medical Cannabis Oral Syringe Under Expanded Compassionate Use Program
A Major Milestone for Texas’ Medical Cannabis Industry as Access Broadens for Patients
Texas Original, the state’s leading medical cannabis provider, has announced the launch of Texas’ first medical cannabis oral syringe, marking a pivotal expansion in patient access under the Texas Compassionate Use Program (TCUP).
The new 0.5-gram syringe, available to registered patients beginning this month, offers a significant alternative to traditional edibles such as gummies. By introducing a new method of administration, the company aims to give physicians and patients greater flexibility in designing individualized treatment plans.
The launch represents the first product innovation among Texas’ licensed dispensing organizations since the passage of House Bill 46, which broadened the state’s medical cannabis laws earlier this year.
Expanding Treatment Options with Full-Spectrum Relief
The newly released oral syringe features Rick Simpson Oil (RSO) — a full-spectrum cannabis extract known for its robust cannabinoid and terpene profile. The oil is derived entirely from Texas Original’s proprietary Texas OG strain, cultivated and processed at the company’s facilities in Central Texas.
RSO is renowned for including not only THC but also the plant’s flavonoids, terpenes, proteins, and other potentially therapeutic compounds, which work together in what researchers describe as the “entourage effect.” This synergy may enhance the overall therapeutic benefits and effectiveness of medical cannabis treatments.
Texas Original CEO Nico Richardson emphasized the company’s mission to expand patient access while maintaining rigorous safety and quality standards.
House Bill 46: A Landmark Expansion of Texas’ Compassionate Use Program
The RSO oral syringe arrives as part of a broader transformation in Texas’ medical cannabis landscape, thanks to House Bill 46 (H.B. 46) — a bipartisan measure that took effect earlier this year.
The legislation made sweeping improvements to the Texas Compassionate Use Program, expanding both qualifying conditions and delivery methods. Key provisions of H.B. 46 include:
New qualifying conditions, such as chronic pain, Crohn’s disease, traumatic brain injury, and terminal illnesses or conditions requiring hospice or palliative care.
Approval for aerosol and vaporized cannabis products, providing faster-acting relief for patients with episodic conditions like post-traumatic stress disorder (PTSD).
Authorization for satellite dispensing locations, allowing medical cannabis to be safely stored and distributed closer to patients, reducing travel barriers and improving accessibility.
According to state officials, these reforms have already broadened access for thousands of Texans, particularly those living in rural areas where obtaining prescriptions was previously difficult.
A Step Toward Innovation: Inside Texas Original’s RSO Syringe
The introduction of the oral syringe underscores Texas Original’s commitment to innovation, patient care, and product diversity. Unlike edibles or capsules, the RSO syringe allows for precise dosing and flexible use, enabling patients to adjust their intake based on symptom severity and tolerance.
Because RSO is full-spectrum, it provides what some medical professionals describe as more comprehensive symptom relief, potentially beneficial for patients with chronic pain, cancer, epilepsy, and neurodegenerative disorders.
The company reports that all batches of RSO undergo third-party lab testing to ensure compliance with Texas’ strict medical cannabis standards for potency, purity, and safety.
Preparing for Expansion: New Bastrop Headquarters to Boost Production
The product launch coincides with preparations for the opening of Texas Original’s new state-of-the-art headquarters in Bastrop, set to become one of the most advanced medical cannabis facilities in the region.
Spanning 75,000 square feet, the facility will feature expanded cultivation space, advanced laboratory testing, and streamlined product distribution. The new headquarters is expected to significantly increase production capacity, supporting future product lines and research initiatives.
With this new infrastructure, Texas Original aims to reduce bottlenecks in the supply chain and accelerate the release of innovative cannabis-based treatments throughout the state.
A Growing Market and a New Era for Patient Access in Texas
Texas’ medical cannabis industry remains one of the most tightly regulated in the country, but changes like H.B. 46 signal growing momentum toward expanded access. Since TCUP’s creation in 2015, the list of qualifying conditions and product options has steadily increased, and Texas Original has been at the forefront of each step forward.
The launch of the RSO syringe is being hailed by patients and advocates as a breakthrough in medical cannabis delivery, offering a discreet, easy-to-use alternative that supports consistent therapeutic outcomes.
As the state continues to refine its medical cannabis framework, companies like Texas Original are expected to play a crucial role in driving innovation, improving patient outcomes, and setting new standards for safety and efficacy in the emerging Southern cannabis market.
Texas Original’s Vision for Compassionate Care
With a clear commitment to patient-centered progress, Texas Original continues to lead the charge in Texas’ evolving cannabis sector. By aligning product innovation with legislative milestones, the company is shaping what compassionate care looks like in a state once known for strict prohibitions.
As more Texans gain access to regulated, high-quality cannabis products, the RSO oral syringe may mark not just the launch of a new product, but the beginning of a more accessible, inclusive future for medical cannabis care in Texas.
